Dr. Sirisak Chanprasert, MD

Dr. Chanprasert practices at UW Medical Center - Montlake in Seattle, Washington, part of University of Washington.

Dr. Chanprasert's NPI, 1336370758, was assigned on August 3, 2009. Dr. Chanprasert holds Washington license MD60528251.

Dr. Chanprasert's primary practice is UW Medical Center - Montlake, at 1959 NE Pacific St Box 356151, Seattle, WA 98195 in King County. The practice phone is (206) 598-3300.

Dr. Chanprasert's primary practice is UW Medical Center - Montlake in Seattle, Washington, part of University of Washington. Dr. Chanprasert is also affiliated with Harborview Medical Center. The medical group on file is UW Physicians. Dmand AI also links Dr. Chanprasert to 1 more hospital and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chanprasert practices, 4 sites in all. Vendor and product names are available with a free account.

Clinical biochemical genetics is Dr. Chanprasert's primary specialty in the NPI Registry, under taxonomy code 207SG0202X. Dr. Chanprasert is licensed in Washington.

CMS data shows 78 Medicare services from Dr. Chanprasert across 3 procedure codes in 2024, for 53 Medicare patients. Medicare paid $6,349 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 53 Medicare patients who saw Dr. Chanprasert in 2024. The largest group is under 65, with 22 patients. 62% of them have high blood pressure, and 55% have high cholesterol. 42% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chanprasert's median patient age at 38, with 58% women.

In 2024, Dr. Chanprasert wrote 69 Medicare Part D claims. 32% of them were for generic drugs. CMS names the drug for 47 of them, across 2 drugs with 11 or more claims each, at $870,081 in total drug cost. In 2023, CMS named 35 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Chanprasert for performance year 2024, reported through an alternative payment model (APM). Dr. Chanprasert accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chanprasert as offering telehealth.

Dmand AI links 24 papers to Dr. Chanprasert, published from 2011 to 2025. 2014 was the busiest year, with 3. The most frequent topics are MELAS Syndrome, Arginine and Citrulline. Dr. Chanprasert has published most often in Am J Emerg Med. Dr. Chanprasert's most frequent co-authors are Fernando Scaglia, MD, Wisit Cheungpasitporn, MD and William James Craigen, MD.

CMS Open Payments shows 3 general payments to Dr. Chanprasert from 2 drug and device companies from 2018 to 2021. Food and beverage make up the largest share, 59% of the total. Sanofi and Genzyme US Companies paid the most, $86.